Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-valent Streptococcus pneumoniae conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 11-valent Streptococcus pneumoniae conjugate vaccine is an investigational pneumococcal conjugate vaccine (PCV) developed by GlaxoSmithKline Biologicals (GSK). It is composed of 11 pneumococcal capsular polysaccharide serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) conjugated to carrier proteins, primarily Protein D (PD) derived from non-typeable Haemophilus influenzae, and Diphtheria Toxoid (DT) for serotypes 6B and 23F. The vaccine is designed to stimulate an active immune response against Streptococcus pneumoniae infections, including pneumonia and invasive pneumococcal disease. It has been evaluated in Phase I/II clinical trials in healthy, pneumococcal vaccine-naive elderly adults (aged 65–85 years) to assess safety, reactogenicity, and immunogenicity, often utilizing novel adjuvant systems to enhance the immune response in this population.
- Other names
- 11vPCV11-valent pneumococcal conjugate vaccine11Pn-PDPCV11PCV-11PCV 11
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)PD (Protein D)
Beyond the preview
Go deeper on 11-valent Streptococcus pneumoniae conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11-valent Streptococcus pneumoniae conjugate vaccine.